The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1561
December 3, 2018
View Complete Issue         Table of Contents 2019 
Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events
December 3, 2018 (Issue: 1561)
The FDA has approved a new 2.5-mg formulation of the direct factor Xa inhibitor rivaroxaban (Xarelto – Janssen) for use in combination with low-dose aspirin to reduce the risk of major cardiovascular events in patients with chronic coronary...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events
Article code: 1561b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.